Back to Press Release List

Advanced Renal Technologies at NephroAsia

January 26, 2004

BELLEVUE, Wash., USA – Advanced Renal Technologies (“ART”), developers of Citrasate® and DRYalysate® citric acid-based dialysate concentrates, announced today they will have exhibit booth D14 at NephroAsia, February 9-12, 2004 in Singapore. “ART is excited to be a part of Asia’s premier nephrology meeting,” said Mike Fulton, managing director of ART, based in Bellevue, Washington (USA). “As a developer of innovative technologies, ART relies on international meetings such as NephroAsia to make important contacts to partner with high quality manufacturers, distributors and academic partners throughout the world.”

Citrasate and DRYalysate are patented acid concentrates using citric acid, a known anticoagulant. ART’s citric acid-based dialysate concentrates are particularly helpful in better dialysis for those patients where heparin is contraindicated, such as heparin antibodies or allergies. The acid concentrate products are also helpful in acute dialysis where there is a risk of bleeding or clotting. Citrasate and DRYalysate have been shown to prevent dialyzer clotting, reduce metabolic acidosis and increase reuse of dialyzers.

Advanced Renal Technologies, Inc. is a privately held company focused on the development of products to improve the treatment of patients with acute and chronic kidney failure. More information about Advanced Renal Technologies, Inc. and its dialysate products may be found at www.citrasate.com.